AbTherx specializes in antibody discovery using its proprietary Atlas™ Mice, which feature full human diversity and optimized B-cell rearrangements to enhance therapeutic antibody development. The company addresses the limitations of traditional transgenic technologies by providing flexible, royalty-free access to its advanced mouse models, enabling efficient and effective drug discovery for a range of therapeutic applications.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional methods of therapeutic antibody discovery often face limitations in generating fully human antibodies with high diversity and developability, particularly against complex targets like GPCRs and ion channels. Existing transgenic technologies may also involve royalty obligations, restricting accessibility for some drug developers.
Solution
AbTherx provides next-generation transgenic mouse technologies, called Atlas™ Mice, designed to overcome these limitations and accelerate therapeutic antibody discovery. These mice are engineered with full human diversity and optimized B-cell rearrangements to enhance the generation of high-quality, fully human antibodies. The Atlas™ platform includes the Full Human Diversity Mouse, the Binary Fixed Light Chain Mouse for bispecific antibody development, and the Long CDR3 Mouse for targeting GPCRs and ion channels. AbTherx offers flexible partnering models, including royalty-free access, to make its advanced mouse models accessible to a wide range of drug developers, from academic innovators to established pharmaceutical companies.
Target Audience
AbTherx serves drug developers of all sizes, from academic innovators and biotech startups to established pharmaceutical companies, seeking to discover and develop therapeutic antibodies against a wide range of targets.
Features
- Atlas™ Mice engineered with full human heavy chain and kappa light chain diversity
- Binary Fixed Light Chain Mouse enables the development of native-like IgG bispecific antibodies with optimized heavy-light chain pairing
- Long CDR3 Mouse utilizes natural mechanisms to generate long CDR3 antibodies for improved targeting of GPCRs and ion channels
- Designed to minimize immunogenicity and developability risks
- Flexible partnering models, including royalty-free options
- Access to CRO partners for full-service antibody discovery